Financials

v3.22.2
CONDENSED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 6,420 $ 6,037
Restricted cash 165 295
Receivables 101 112
Inventory 469 293
Prepaid expenses and other current assets 544 480
Discontinued operations - current assets 14 12
Total current assets 7,713 7,229
Property and equipment, net 317 420
Other assets 48 48
Operating lease right-of-use asset 241 297
Total assets 8,319 7,994
Current liabilities:    
Accounts payable 443 795
Accrued clinical trials expenses 36 9
Other accrued liabilities 631 314
Operating lease liability, current 117 112
Deferred grant revenue 165 295
Discontinued operations - current liabilities 1,132 1,144
Total current liabilities 2,524 2,669
Operating lease liability, non-current 128 187
Total liabilities 2,652 2,856
Stockholders' equity:    
Common stock, at amounts paid-in, $0.001 par value per share; 225,000,000shares authorized, 14,629,217 and 9,914,158 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively. 15 10
Additional paid-in capital 386,709 381,183
Accumulated deficit (381,057) (376,055)
Total stockholders' equity 5,667 5,138
Total liabilities and stockholders' equity $ 8,319 $ 7,994

Source

v3.22.2
CONDENSED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Revenues:        
Total revenues $ 150 $ 445 $ 341 $ 1,127
Operating expenses:        
Cost of goods sold 0 89   199
Research and development 974 1,646 2,383 3,523
General and administrative 1,618 1,035 2,939 2,362
Total operating expenses 2,592 2,770 5,322 6,084
Loss from operations (2,442) (2,325) (4,981) (4,957)
Other income (expense):        
Interest income (expense), net 5 0 5 (2)
Gain on debt extinguishment 0 661 0 661
Other expense, net (25) (16) (26) (23)
Other income (expense), net (20) 645 (21) 636
Net loss $ (2,462) $ (1,680) $ (5,002) $ (4,321)
Basic net loss per common share $ (0.18) $ (0.17) $ (0.41) $ (0.45)
Diluted net loss per common share $ (0.18) $ (0.17) $ (0.41) $ (0.45)
Weighted average shares used in computing basic net loss per common share 13,692 9,864 12,218 9,578
Weighted average shares used in computing diluted net loss per common share 13,692 9,864 12,218 9,578
License revenue        
Revenues:        
Total revenues $ 3 $ 3 $ 5 $ 5
Product revenue        
Revenues:        
Total revenues 0 89   200
Grant revenue        
Revenues:        
Total revenues $ 147 $ 353 $ 336 $ 922

Source

v3.22.2
CONDENSED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Cash flows from operating activities:    
Net loss $ (5,002) $ (4,321)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 103 112
Non-cash interest expense 0 2
Non-cash gain on debt extinguishment 0 (661)
Stock-based milestone payment 50 0
Stock-based compensation 497 695
Other 2 (10)
Changes in operating assets and liabilities:    
Receivables 11 781
Inventory (176) 199
Prepaid expenses and other assets (66) (15)
Accounts payable (363) (1,079)
Accrued sales allowances 0 (60)
Deferred grant revenue (130) 0
Other accrued liabilities 343 (199)
Net cash used in operating activities (4,731) (4,556)
Cash flows from investing activities:    
Purchases of property and equipment 0 (18)
Net cash used in investing activities 0 (18)
Cash flows from financing activities:    
Net proceeds from equity offering 4,980 8,841
Net proceeds from the exercises of common stock warrants 4 0
Net cash provided by financing activities 4,984 8,841
Net increase in cash, cash equivalents and restricted cash 253 4,267
Cash, cash equivalents and restricted cash at beginning of period 6,332 5,413
Cash, cash equivalents and restricted cash at end of period $ 6,585 $ 9,680

Source